{
  "drug_name": "Cyclosporine",
  "generic_name": [
    "CYCLOSPORINE OPHTHALMIC SOLUTION"
  ],
  "brand_names": [
    "VEVYE"
  ],
  "drug_interactions": [],
  "warnings": [],
  "adverse_reactions": [
    "6 ADVERSE REACTIONS The most common adverse reaction following the use of VEVYE were instillation site reactions (8%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, ccontact Harrow Eye, LLC \u00ae at 833-4HARROW or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical trials with 738 subjects receiving at least 1 dose of VEVYE, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%)."
  ],
  "contraindications": [
    "4 CONTRAINDICATIONS None. None. ( 4 )"
  ],
  "dosage_administration": [
    "2 DOSAGE AND ADMINISTRATION Wash hands before using. Instill one drop of VEVYE twice a day in each eye approximately 12 hours apart. If used with other eye drops, a 15-minute interval between products should occur. Instill one drop of VEVYE twice a day in each eye approximately 12 hours apart. ( 2 )"
  ],
  "indications": [
    "1 INDICATIONS AND USAGE VEVYE is indicated for the treatment of the signs and symptoms of dry eye disease. VEVYE (cyclosporine ophthalmic solution) 0.1% is a calcineurin inhibitor immunosuppressant indicated for the treatment of the signs and symptoms of dry eye disease. ( 1 )"
  ],
  "fetched_at": "2025-09-30T20:55:32.075869",
  "source": "OpenFDA"
}